Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Viral Structure00:56

Viral Structure

61.4K
Viruses are extraordinarily diverse in shape and size, but they all have several structural features in common. All viruses have a core that contains a DNA- or RNA-based genome. The core is surrounded by a protective coat of proteins called the capsid. The capsid is composed of subunits called capsomeres. The capsid and genome-containing core are together known as the nucleocapsid.
61.4K
Vaccinations01:51

Vaccinations

43.1K
Overview
43.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

γδ T cells at the interface of innate and adaptive immunity in cancer.

Journal for immunotherapy of cancer·2026
Same author

A Case for Anti-IgE Vaccination.

Allergy·2026
Same author

Post-authorisation experience and reported adverse events following use of a virus-like particle chikungunya vaccine, United States and Germany, up to August 2025.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2025
Same author

Targeted Lymph Node Immunization with Serotype-Specific Dengue VLP Vaccines Enhances Antibody Avidity and Specificity.

Vaccines·2025
Same author

Versatile and Scalable Nanoparticle Vaccine as a Scaffold Against Newly Emerging Influenza Viruses.

Viruses·2025
Same author

The impact of viral evolution on vaccine development for SARS-CoV-2.

Current opinion in immunology·2025

Related Experiment Video

Updated: May 20, 2025

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

21.8K

Virus-like particles: a versatile and effective vaccine platform.

Martin F Bachmann1, Pierre van Damme2, Florian Lienert3

  • 1Department of Immunology, University Hospital of Bern, Switzerland; University of Oxford, UK.

Expert Review of Vaccines
|May 19, 2025
PubMed
Summary

Virus-like particles (VLPs) offer a safer alternative to traditional vaccines. This review highlights their structure, manufacturing, and successful clinical applications, paving the way for future VLP vaccine development.

Keywords:
Efficacyimmunizationvaccinevaccine developmentvirus-like particle

More Related Videos

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

3.5K
A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

2.5K

Related Experiment Videos

Last Updated: May 20, 2025

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

21.8K
Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

3.5K
A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

2.5K

Area of Science:

  • Vaccinology
  • Biotechnology
  • Virology

Background:

  • Traditional vaccines face limitations like reduced immunogenicity and safety concerns.
  • Virus-like particles (VLPs) have emerged as a promising alternative vaccine platform.
  • VLPs mimic native viruses but are non-infectious, addressing traditional vaccine drawbacks.

Purpose of the Study:

  • To provide an overview of virus-like particle (VLP) vaccine technology.
  • To discuss the structure, design, and manufacturing of VLPs for vaccine development.
  • To review the clinical efficacy and safety of approved and investigational VLP vaccines.

Main Methods:

  • Literature review of VLP vaccine development and clinical data.
  • Analysis of VLP structure, assembly, and production methods.
  • Summary of clinical trial outcomes for VLP vaccines against various pathogens.

Main Results:

  • VLPs are self-assembling, non-infectious viral protein structures.
  • Approved VLP vaccines demonstrate significant efficacy and safety.
  • VLP vaccines are in late-stage development for respiratory syncytial virus and human metapneumovirus.

Conclusions:

  • VLPs represent a versatile and effective platform for vaccine development.
  • Their safety and immunogenicity profile make them attractive for global immunization.
  • Advancements in VLP technology promise highly effective future vaccines.